Brainstorm issues 2024 letter to shareholders

New york , dec. 30, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a letter to shareholders.     dear valued shareholders, 2024 has been a very productive year for brainstorm cell therapeutics, defined by remarkable milestones and achievements that have brought us closer to our mission of delivering groundbreaking therapies for neurodegenerative diseases.
BCLI Ratings Summary
BCLI Quant Ranking